ASArthur Sorlin

Arthur Sorlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arthur Sorlin has a total of 714 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PHD Inhibitor Vadadustat: The First Drug Therapy for Triosephosphate Isomerase Deficiency

    by Emmanuel Scalais, Priyal Patel, Sidney Satterfield, Mylène Donge, Raphael Laschiazza, Arthur Sorlin, Presley Roberts, Joseph R. Figura, Ella R. Donahue, Cindy Cui, et al.

    Background/Objectives: Triosephosphate isomerase deficiency (TPI Df) is an ultra-rare autosomal recessive glycolytic disorder characterized by symptoms of hemolytic anemia, progressive neuromuscular dysfunction, and early mortality. The TPI1E105D mutation (TPI1 variant p.Glu105Asp) accounts for most cases, though TPI Df can also arise from other pathogenic variants, including compound heterozygous TPI1 variants such as TPI1R5G/f.s (p.(Arg5Gly)/p.(Ile151Serfs*3)). TPI1R5G/f.s presents with an atypical predominantly neurological phenotype characterized by severe dystonia, dysarthria, basal ganglia involvement, and cognitive impairment, without hemolytic anemia or peripheral neuromuscular disease. Regardless of the causative allele(s), reduced mutant TPI protein stability is the central pathogenic mechanism. We previously hypothesized that pharmacological inhibition of prolyl hydroxylase domain (PHD) enzymes, leading to hypoxia-inducible factor (HIF) stabilization, could increase TPI protein levels and attenuate disease severity. Methods: We evaluated PHD inhibitors, including vadadustat and roxadustat, in patient-derived TPI1E105D/E105D fibroblasts and Tpi1E105D/E105D mouse models. In addition, vadadustat was administered off-label as compassionate therapy to a TPI Df patient. Studies assessed TPI protein levels, enzymatic activity, hematological parameters, and clinical outcomes. Results: In FB303 patient fibroblasts, vadadustat (100 μM) and roxadustat (100 μM) increased TPI protein levels by ~45% and ~68%, and TPI enzymatic activity by ~191% and ~258%, respectively. In Tpi1E105D/E105D mice, vadadustat significantly increased TPI levels in liver, kidney, and muscle tissues along with partial improvement in neuromuscular function, as assessed by rotarod performance. Supported by these findings, compassionate off-label administration with vadadustat/Vafseo was initiated in a single TPI1R5G/f.s. patient. Treatment was associated with a progressive increase in residual TPI enzymatic activity, clinical stabilization, and meaningful neurological improvement, predominantly affecting left-sided motor function, including improved upper-limb dexterity, recovery of functional grasping, and complete resolution of myoclonic-like movements. Conclusions: This report provides the first in vivo evidence that pharmacological stabilization of mutant TPI1 protein may represent a novel therapeutic strategy for TPI deficiency. Furthermore, the findings establish PHD inhibitors, such as vadadustat, as excellent candidates for disease-modifying therapy of TPI Df warranting further development and clinical investigation.

  • Caractérisation génomique des anomalies de la pigmentation cutanée en mosaïque

    by Arthur Sorlin

    Introduction : Les dyschromies cutanées en mosaïque ont fait suspecter de longue date l’implication d’un mosaïcisme génétique sous-jacent. Ces évènements post-zygotiques sont cependant difficilement détectables par les techniques conventionnelles. Ainsi, les bases génétiques des dyschromies en mosaïque étaient restées mal connues. Matériel et méthodes : la cohorte M.U.S.T.A.R.D rassemble des échantillons d’ADN de biopsies cutanées de patients porteurs d’un mosaïcisme pigmentaire. Après une analyse phénotypique spécialisée, ces échantillons sont étudiés en séquençage à forte profondeur, d’exome (ES) en trio, ou ciblé. Les données sont analysées à l’aide d’un pipeline dédié, permettant la détection de variations ponctuelles en mosaïque (mSNV) mais également de diverses anomalies chromosomiques en mosaïque. Résultats : De 2013 à 2019, 101 patients ont été inclus. Un ES a été réalisé pour 56 patients, identifiant un mSNV chez 12 patients, dans 7 gènes dont 4 nouveaux (RHOA, DOCK1, GNA13, TFE3), et une anomalie chromosomique chez 17 patients. Une étude ciblée de ces gènes chez 40 autres patients était positive pour 17, soit un rendement diagnostique global à 55% (46/84). Conclusion : Ce travail illustre l’importance d’une approche bioinformatique polyvalente, combinée à une expertise clinique, pour la détermination des causes génétiques des dyschromies cutanées en mosaïque. Il a également mis en évidence le rôle de la voie de signalisation dépendant des Rho GTPases, faisant progresser notre compréhension de la physiopathologie des dyschromies en mosaïque, une étape nécessaire à l’amélioration de la prise en charge de ces patients porteurs de maladies rares et complexes.

  • Open Access

    Investigating the neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies

    by Sébastien Küry, Janelle E. Stanton, Geeske M. van Woerden, Amélie Bosc-Rosati, Tzung-Chien Hsieh, Lise Bray, Marielle Oloudé, Cory Rosenfelt, Marie Pier Scott-Boyer, Victoria Most, et al.

    Neurodevelopmental proteasomopathies are a group of disorders caused by variants in proteasome subunit genes, that disrupt protein homeostasis and brain development through poorly characterized mechanisms. Here, we report 26 distinct variants in PSMC5 , encoding the AAA⁺ ATPase subunit PSMC5/RPT6, in individuals with syndromic neurodevelopmental conditions. Combining genetic, multi-omics and biochemical approaches across cellular models and Drosophila , we unveil the essential role of proteasomes in sustaining key cellular processes. Loss of PSMC5/RPT6 function impairs proteasome activity, leading to protein aggregation, disruption of mitochondrial homeostasis, and dysregulation of lipid metabolism and immune signaling. It also compromises synaptic balance, neuritogenesis, and neural progenitor cell stemness, causing deficits in higher-order functions, including learning and locomotion. Pharmacological targeting of integrated stress response kinases reveals a mechanistic link between proteotoxic stress and spontaneous type I interferon activation. These findings expand our understanding of proteasome-dependent quality control in neurodevelopment and suggest potential therapeutic strategies for neurodevelopmental proteasomopathies.


  • Open Access

    Newly Identified TPI Deficiency Treatments Function for Novel Disease-Causing Allele, TPI1R5G

    by Joseph R. Figura, Presley Roberts, Riley Sawka, Maci Chambers, Marcelo Claudio, Laura L. Vollmer, Andreas Vogt, Gregg E. Homanics, Eduard van Beers, Mylene Donge, et al.

    Background/Objectives: Triosephosphate Isomerase (TPI) is a glycolytic enzyme known to be associated with TPI deficiency, a severe form of childhood-onset glycolytic enzymopathy associated with hemolytic anemia, neuromuscular impairment and early death. Most often the disease results from the common TPI1E105D mutation, which can be either homozygous or compound heterozygous with another allele. Methods: We purified TPIR5G protein, studied mutant protein biochemistry, established and characterized TPIR5G/f.s.patient cells, and investigated newly identified compounds for their efficacy in vitro using Western blot and TPI activity assays. Results: We identified novel TPI1 alleles that result in TPI Deficiency with an atypical presentation lacking anemia and with more slowly developing neurologic and locomotor impairment. The patient was found to be compound heterozygous with a missense mutation resulting in an R5G amino acid substitution and a frameshift mutation that is a predicted null allele. To better understand disease pathogenesis in this patient, we expressed and purified the TPIR5G human protein and studied it biochemically in addition to studying TPIR5G/f.s.patient cells. We discovered that purified TPIR5G protein has wildtype activity with modestly increased dimer stability. We also discovered that steady-state TPI protein levels were markedly reduced, suggesting that the instability of the mutant protein underlies disease pathogenesis. We tested compounds recently identified in a screen for novel TPI Df therapies for their efficacy in TPIR5G/f.s.patient cells. All three compounds significantly increased TPI protein levels in patient cells. As expected, since the mutant protein retains essentially wild type activity, the increase in TPI protein levels also resulted in a significant increase in TPI activity. Conclusions: These results establish TPIR5G as a TPI Df allele, demonstrate that reduced stability of the mutant protein underlies pathogenesis akin to other disease-causing alleles, and suggest that recently discovered developing therapies will likely function broadly and should be developed as potential TPI Df therapies.


  • Open Access

    ARID2-related disorder: further delineation of the clinical phenotype of 27 novel individuals and description of an epigenetic signature

    by Clara Houdayer, Kathleen Rooney, Liselot van der Laan, Céline Bris, Mariëlle Alders, Angela Bahr, Giulia Barcia, Clarisse Battault, Anais Begemann, Dominique Bonneau, et al.

    Rare genetic variants in ARID2 are responsible for a recently described neurodevelopmental condition called ARID2-related disorder (ARID2-RD). ARID2 belongs to PBAF, a unit of the SWI/SNF complex, which is a chromatin remodeling complex. This work aims to further delineate the phenotypic spectrum of ARID2-RD, providing clinicians with additional data for better care and aid in the future diagnosis of this condition. We obtained the genotypes and phenotypes of 27 previously unreported individuals with ARID2-RD and compared this series with findings in the literature. We also assessed peripheral blood DNA methylation profiles in individuals with ARID2-RD compared to episignatures of controls, unresolved cases, and other neurodevelopmental disorders. The main clinical features of ARID2-RD are developmental delay, speech disorders, intellectual disability (ID), behavior problems, short stature, and various dysmorphic and ectodermal features. Genome-wide differential methylation analysis revealed a global hypermethylated profile in ARID2-RD that could aid in reclassifying variants of uncertain significance. Our study doubles the number of reported individuals with ARID2 pathogenic variants to 53. It confirms loss-of-function as a pathomechanism and shows the absence of a clear genotype-phenotype correlation. We provide evidence for a unique DNA methylation episignature for ARID2-RD and further delineate the ARID2-associated phenotype.


  • Open Access

    A postzygotic GNA13 variant upregulates the RHOA/ROCK pathway and alters melanocyte function in a mosaic skin hypopigmentation syndrome

    by Rana El Masri, Alberto Iannuzzo, Paul Kuentz, Rachida Tacine, Marie Vincent, Sébastien Barbarot, Fanny Morice-Picard, Franck Boralevi, Naia Oillarburu, Juliette Mazereeuw-Hautier, et al.

    The genetic bases of mosaic pigmentation disorders have increasingly been identified, but these conditions remain poorly characterised, and their pathophysiology is unclear. Here, we report in four unrelated patients that a recurrent postzygotic mutation in GNA13 is responsible for a recognizable syndrome with hypomelanosis of Ito associated with developmental anomalies. GNA13 encodes Gα13, a subunit of αβγ heterotrimeric G proteins coupled to specific transmembrane receptors known as G-protein coupled receptors. In-depth functional investigations revealed that this R200K mutation provides a gain of function to Gα13. Mechanistically, we show that this variant hyperactivates the RHOA/ROCK signalling pathway that consequently increases actin polymerisation and myosin light chains phosphorylation, and promotes melanocytes rounding. Our results also indicate that R200K Gα13 hyperactivates the YAP signalling pathway. All these changes appear to affect cell migration and adhesion but not the proliferation. Our results suggest that hypopigmentation can result from a defect in melanosome transfer to keratinocytes due to cell shape alterations. These findings highlight the interaction between heterotrimeric G proteins and the RHOA pathway, and their role in melanocyte function.


  • Open Access

    Expectations, needs and mid-term outcomes in people accessing to secondary findings from ES: 1st French mixed study (FIND Study)

    by Eléonore Viora-Dupont, Françoise Robert, Aline Chassagne, Aurore Pélissier, Stéphanie Staraci, Damien Sanlaville, Patrick Edery, Gaetan Lesca, Audrey Putoux, Linda Pons, et al.

    Generation and subsequently accessibility of secondary findings (SF) in diagnostic practice is a subject of debate around the world and particularly in Europe. The French FIND study has been set up to assess patient/parent expectations regarding SF from exome sequencing (ES) and to collect their real-life experience until 1 year after the delivery of results. 340 patients who had ES for undiagnosed developmental disorders were included in this multicenter mixed study (quantitative N = 340; qualitative N = 26). Three groups of actionable SF were rendered: predisposition to late-onset actionable diseases; genetic counseling; pharmacogenomics. Participants expressed strong interest in obtaining SF and a high satisfaction level when a SF is reported. The medical actionability of the SF reinforced parents’ sense of taking action for their child and was seen as an opportunity. While we observed no serious psychological concerns, we showed that these results could have psychological consequences, in particular for late-onset actionable diseases SF, within families already dealing with rare diseases. This study shows that participants remain in favor of accessing SF despite the potential psychological, care, and lifestyle impacts, which are difficult to anticipate. The establishment of a management protocol, including the support of a multidisciplinary team, would be necessary if national policy allows the reporting of these data.


  • Open Access

    Unveiling the crucial neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies

    by Sébastien Küry, Janelle E. Stanton, Geeske van Woerden, Tzung-Chien Hsieh, Cory Rosenfelt, Marie Pier Scott-Boyer, Victoria Most, Tianyun Wang, Jonas Johannes Papendorf, Charlotte de Konink, et al.

    Neurodevelopmental proteasomopathies represent a distinctive category of neurodevelopmental disorders (NDD) characterized by genetic variations within the 26S proteasome, a protein complex governing eukaryotic cellular protein homeostasis. In our comprehensive study, we identified 23 unique variants in PSMC5 , which encodes the AAA-ATPase proteasome subunit PSMC5/Rpt6, causing syndromic NDD in 38 unrelated individuals. Overexpression of PSMC5 variants altered human hippocampal neuron morphology, while PSMC5 knockdown led to impaired reversal learning in flies and loss of excitatory synapses in rat hippocampal neurons. PSMC5 loss-of-function resulted in abnormal protein aggregation, profoundly impacting innate immune signaling, mitophagy rates, and lipid metabolism in affected individuals. Importantly, targeting key components of the integrated stress response, such as PKR and GCN2 kinases, ameliorated immune dysregulations in cells from affected individuals. These findings significantly advance our understanding of the molecular mechanisms underlying neurodevelopmental proteasomopathies, provide links to research in neurodegenerative diseases, and open up potential therapeutic avenues.


  • Molecular consequences of PQBP1 deficiency, involved in the X-linked Renpenning syndrome

    by Jérémie Courraud, Camille Engel, Angélique Quartier, Nathalie Drouot, Ursula Houessou, Damien Plassard, Arthur Sorlin, Elise Brischoux-Boucher, Evan Gouy, Lionel Van Maldergem, et al.

    Mutations in the PQBP1 gene (polyglutamine-binding protein-1) are responsible for a syndromic X-linked form of neurodevelopmental disorder (XL-NDD) with intellectual disability (ID), named Renpenning syndrome. PQBP1 encodes a protein involved in transcriptional and post-transcriptional regulation of gene expression. To investigate the consequences of PQBP1 loss, we used RNA interference to knock-down (KD) PQBP1 in human neural stem cells (hNSC). We observed a decrease of cell proliferation, as well as the deregulation of the expression of 58 genes, comprising genes encoding proteins associated with neurodegenerative diseases, playing a role in mRNA regulation or involved in innate immunity. We also observed an enrichment of genes involved in other forms of NDD (CELF2, APC2, etc). In particular, we identified an increase of a non-canonical isoform of another XL-NDD gene, UPF3B, an actor of nonsense mRNA mediated decay (NMD). This isoform encodes a shorter protein (UPF3B_S) deprived from the domains binding NMD effectors, however no notable change in NMD was observed after PQBP1-KD in fibroblasts containing a premature termination codon. We showed that short non-canonical and long canonical UPF3B isoforms have different interactomes, suggesting they could play distinct roles. The link between PQBP1 loss and increase of UPF3B_S expression was confirmed in mRNA obtained from patients with pathogenic variants in PQBP1, particularly pronounced for truncating variants and missense variants located in the C-terminal domain. We therefore used it as a molecular marker of Renpenning syndrome, to test the pathogenicity of variants of uncertain clinical significance identified in PQPB1 in individuals with NDD, using patient blood mRNA and HeLa cells expressing wild-type or mutant PQBP1 cDNA. We showed that these different approaches were efficient to prove a functional effect of variants in the C-terminal domain of the protein. In conclusion, our study provided information on the pathological mechanisms involved in Renpenning syndrome, but also allowed the identification of a biomarker of PQBP1 deficiency useful to test variant effect.


  • Genetic causes of macrozoospermia and proposal for an optimized genetic diagnosis strategy based on sperm parameters

    by Alicia Coudert, Caroline Cazin, Amir Amiri-Yekta, Selima Fourati Ben Mustapha, Raoudha Zouari, Julien Bessonat, Abdelali Zoghmar, Antoine Clergeau, Catherine Metzler-Guillemain, Chema Triki, et al.